Art. -Nr.: HY-B0012

Pamidronic acid

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Pamidronic acid, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.05%
CAS. Nr.: 40391-99-9
Formel: C₃H₁₁NO₇P₂
Molecular Weight:235.07

Speicherung:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Pamidronic acid Chemical Structure

CAS. Nr.: 40391-99-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen :

Alle Wnt Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
13762	IC₅₀	33.6 μM Compound: 38	Antiproliferative activity against rat 13762 cell line Antiproliferative activity against rat 13762 cell line	[PMID: 16970405]
HepG2	IC₅₀	>200 μM Compound: Pamidronate	Antimalarial activity against Plasmodium berghei NK65 infected in human HepG2 cells after 48 hrs by RT-PCR Antimalarial activity against Plasmodium berghei NK65 infected in human HepG2 cells after 48 hrs by RT-PCR	[PMID: 20457823]
HFF	IC₅₀	38 μM Compound: 20	In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells) In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)	[PMID: 15857119]
MCF7	IC₅₀	141 μM Compound: 38	Antiproliferative activity against human MCF7 cell line by MTT assay Antiproliferative activity against human MCF7 cell line by MTT assay	[PMID: 16970405]
MCF7	IC₅₀	22.9 μM Compound: Pamidronate	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay	[PMID: 33132173]
NCI-H460	IC₅₀	71.8 μM Compound: 38	Antiproliferative activity against human NCI-H460 cell line by MTT assay Antiproliferative activity against human NCI-H460 cell line by MTT assay	[PMID: 16970405]
SF-268	IC₅₀	408 μM Compound: 38	Antiproliferative activity against human SF-268 cell line by MTT assay Antiproliferative activity against human SF-268 cell line by MTT assay	[PMID: 16970405]
T-cell	EC₅₀	43 μM Compound: 1	Effective concentration against human Gamma delta T cells Effective concentration against human Gamma delta T cells	[PMID: 15828834]
T-cell	EC₅₀	5.66 μM Compound: pamidronate	Effective concentration to activate gammadelta T cells Effective concentration to activate gammadelta T cells	[PMID: 12383012]
T-cell	IC₅₀	62 μM Compound: 34	Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release	[PMID: 14711309]
T-cell	IC₅₀	941 μM Compound: 34	Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL	[PMID: 14711309]
Vero	IC₅₀	60 μM Compound: 5	Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum	[PMID: 11300872]

In Vitro

Pamidronic acid (0.001-1000 µM, 72 h) inhibits the cell viability of osteosarcoma cells POS, HMPOS and COS31, exhibits no cytotoxicity to fibroblasts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

POS, HMPOS and COS31
Concentration:

0.001-1000 µM
Incubation Time:

72 h
Result:

Inhibited the cell viability.

In Vivo

Pamidronic acid (3 mg/kg, ear vein injection, once monthly for 14 weeks) improves the bone structure, alleviates the degenerative changes of cartilage, exhibits protective effect against osteoarthritis in rabbit models^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Anterior cruciate ligament transection (ACLT)-induced osteoarthritis in rabbits^[3]
Dosage:

3 mg/kg
Administration:

ear vein injection, once monthly for 14 weeks
Result:

Increased bone volume fraction (BV/TV), trabecular thickness (TbTh) and trabecular number (TbN).
Reduced the erosion of cartilage surface, increase the content of chondrocytes and matrix.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 40391-99-9
Appearance Solid
Molecular Weight 235.07
Formel C₃H₁₁NO₇P₂
Color White to off-white
SMILES

OC(P(O)(O)=O)(P(O)(O)=O)CCN
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 5 mg/mL (21.27 mM; ultrasonic and warming and heat to 80°C)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.2541 mL

21.2703 mL

42.5405 mL

5 mM

0.8508 mL

4.2541 mL

8.5081 mL

10 mM

0.4254 mL

2.1270 mL

4.2541 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 2 mg/mL (8.51 mM); Clear solution; Need ultrasonic

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Ashton JA, et al. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cellsfrom dogs. Am J Vet Res. 2005 May;66(5):885-92. [Content Brief]

[2]. Xu Y, et al. Pamidronate Disodium Leads to Bone Necrosis via Suppression of Wnt/β-Catenin Signaling in Human Bone Marrow Mesenchymal Stem Cells In Vitro. J Oral Maxillofac Surg. 2017 Mar 23. [Content Brief]

[3]. Lv Y, et al. Effects of pamidronate disodium on the loss of osteoarthritic subchondral bone and the expression of cartilaginous and subchondral osteoprotegerin and RANKL in rabbits. BMC Musculoskelet Disord. 2014 Nov 6;15:371. [Content Brief]

[4]. Kovacs R, et al. The synthesis of pamidronic derivatives in different solvents: An optimization and a mechanistic study[J]. Heteroatom Chemistry, 2014, 25(3): 186-194.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	4.2541 mL	21.2703 mL	42.5405 mL	106.3513 mL
	5 mM	0.8508 mL	4.2541 mL	8.5081 mL	21.2703 mL
	10 mM	0.4254 mL	2.1270 mL	4.2541 mL	10.6351 mL
	15 mM	0.2836 mL	1.4180 mL	2.8360 mL	7.0901 mL
	20 mM	0.2127 mL	1.0635 mL	2.1270 mL	5.3176 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Pamidronic acid

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Pamidronic acid

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Extracellular Vesicles (EVs) Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Pattern Recognition Receptors Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Pamidronic acid

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen

Alle Wnt Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Pamidronic acid Related Classifications

HY-B0012 Related Classifications